Evidence map›Paper›PMID 21304100›Full record

ArticleBlood2011

Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes.

Zhi-Jian Liu, Joseph Italiano, Francisca Ferrer-Marin, Ravi Gutti, Matthew Bailey, Brandon Poterjoy, Lisa Rimsza, Martha Sola-Visner

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 106 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. TMEA, a Polyphenol inFrontiers in cell and developmental biology · 2021
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Zhi-Jian LiuDivision of Newborn Medicine, Children's Hospital Boston, Boston, MA, USA.
Joseph Italiano
Francisca Ferrer-Marin
Ravi Gutti
Matthew Bailey
Brandon Poterjoy
Lisa Rimsza
Martha Sola-Visner
Boston Children's Hospital · USBrigham and Women's Hospital · USDrexel University · USUniversity of Arizona · US

Funding

Prolonged and Severe Thrombocytopenia in NeonatesR01HL069990 · NHLBI · UNIVERSITY OF FLORIDA · PI SOLA-VISNER, MARTHA C. · 2002 to 2015
$2.8M
NHLBI NIH HHS R01 HL069990
6 · The paper itself

Abstract

Multiple observations support the existence of developmental differences in megakaryocytopoiesis. We have previously shown that neonatal megakaryocyte (MK) progenitors are hyperproliferative and give rise to MKs smaller and of lower ploidy than adult MKs. Based on these characteristics, neonatal MKs have been considered immature. The molecular mechanisms underlying these differences are unclear, but contribute to the pathogenesis of disorders of neonatal megakaryocytopoiesis. In the present study, we demonstrate that low-ploidy neonatal MKs, contrary to traditional belief, are more mature than adult low-ploidy MKs. These mature MKs are generated at a 10-fold higher rate than adult MKs, and result from a developmental uncoupling of proliferation, polyploidization, and terminal differentiation. This pattern is associated with up-regulated thrombopoietin (TPO) signaling through mammalian target of rapamycin (mTOR) and elevated levels of full-length GATA-1 and its targets. Blocking of mTOR with rapamycin suppressed the maturation of neonatal MKs without affecting ploidy, in contrast to the synchronous inhibition of polyploidization and cytoplasmic maturation in adult MKs. We propose that these mechanisms allow fetuses/neonates to populate their rapidly expanding bone marrow and intravascular spaces while maintaining normal platelet counts, but also set the stage for disorders restricted to fetal/neonatal MK progenitors, including the Down syndrome-transient myeloproliferative disorder and the thrombocytopenia absent radius syndrome.

Indexed as

Cell DifferentiationFetal BloodGATA1 Transcription FactorHematopoietic Stem CellsHumansInfant, NewbornMegakaryocytesMicroscopy, Electron, TransmissionSignal TransductionThrombopoiesisThrombopoietinTOR Serine-Threonine KinasesTranscription FactorsUp-RegulationGATA1 protein, humanGATA1 Transcription FactorMTOR protein, humanThrombopoietinTOR Serine-Threonine KinasesTranscription Factors

Identifiers

PMID21304100
PMCPMC3087534
OpenAlexW2088383848

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.